Peer-reviewedLicence not statedImmunotherapy
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
- 1Department of Clinical Pharmacy, Yunnan Qujing Central Hospital (Qujing First People’s Hospital), Qujing, Yunnan, China
- 2Department of Neurology, Yunnan Qujing Central Hospital (Qujing First People’s Hospital), Qujing, Yunnan, China
- 3Department of Emergency Medicine, Yunnan Qujing Central Hospital (Qujing First People’s Hospital), Qujing, Yunnan, China
Related
- Establishment of an Anti-Nephrin Autoantibody Assay and the Predictive and Diagnostic Significance of Pre-treatment Antibody Titers in Pediatric Nephrotic Syndrome
- Hyperacute Guillain-Barré Syndrome: A Pathophysiological Interpretation
- Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barré Syndrome of a Severe Refractory Case
- Reply to the Letter “Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barré Syndrome of a Severe Refractory Case”
- Efgartigimod and Steroid Pulse Therapy as an Early Fast-acting Treatment Strategy for Anti-MUSK Myasthenic Crisis
BibTeX
@article{wang2026efgartigimod,
title = {{Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review}},
author = {Yueqi Wang and Siqi Wang and Huijuan Fan and Wenjun Sun and Yanmei Fa and Yuxian Yang and Ronghua Chen and Kang Du and Shanshan Wu},
journal = {Immunotherapy},
year = {2026},
month = oct,
doi = {10.1080/1750743x.2026.2742742},
url = {https://doi.org/10.1080/1750743x.2026.2742742},
}
RIS
TY - JOUR
TI - Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
AU - Yueqi Wang
AU - Siqi Wang
AU - Huijuan Fan
AU - Wenjun Sun
AU - Yanmei Fa
AU - Yuxian Yang
AU - Ronghua Chen
AU - Kang Du
AU - Shanshan Wu
PY - 2026
DA - 2026/10/08
JO - Immunotherapy
DO - 10.1080/1750743x.2026.2742742
UR - https://doi.org/10.1080/1750743x.2026.2742742
SN - 1750-743X
SN - 1750-7448
ER -